Biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
Genmab A/S, a biotechnology company based in Copenhagen, Denmark, specializes in the development of antibody therapeutics for cancer and other diseases. Notable products include DARZALEX, a human monoclonal antibody for multiple myeloma, and teprotumumab for thyroid eye disease. The company also markets ofatumumab for chronic lymphocytic leukemia and multiple sclerosis, as well as Amivantamab for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC).
Genmab's product portfolio features daratumumab, used for multiple myeloma, non-multiple myeloma blood cancers, and AL amyloidosis. Additional therapies in development include GEN1047, tisotumab vedotin for various cancers, DuoBody-PD-L1x4-1BB, DuoBody-CD40x4-1BB for solid tumors, and Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia. The pipeline also includes HexaBody-CD38 and DuoHexaBody-CD37 for hematological malignancies, along with several products in Phase 2 trials such as Teclistamab, Camidanlumab tesirine, and JNJ-64007957 for multiple myeloma.
Genmab has established numerous collaborations to advance its research and development initiatives. The company has a commercial license and collaboration agreement with Seagen Inc. for co-developing tisotumab vedotin and partnerships with CureVac AG for mRNA-based antibody products, AbbVie for Epcoritamab development, and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Founded in 1999, Genmab continues to expand its impact in biotechnology with approximately 20 active pre-clinical programs.